Indivior's Monthly Injectable Buprenorphine Wins Panel Backing; US FDA May Limit Dosage

Advisory committee votes 18 to 1 for approval of the opioid abuse disorder treatment with restricted distribution; members advise post-market studies, registry.

vialandmultiplesyringes_1200x675

While several members expressed concerns about the data supporting the safety and efficacy of Indivior PLC's once-monthly injectable buprenorphine, a US FDA advisory panel voted 18 to 1 in favor of its approval with a Risk Evaluation and Mitigation Strategy (REMS) restricting distribution to certain healthcare settings.

Panelists agreed that the product, RBP-6000, provides an effective new treatment for opioid abuse disorder. Several felt the approval should...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers